Aims & Scope – Drug Delivery Letters

ISSN (Print): 2210-3031
ISSN (Online): 2210-304X

Latest Issue: Volume 12 , Issue 2 , 2022

Aims & Scope

Drug Delivery Letters publishes short papers and mini-reviews in all important aspects of drug delivery, gene delivery, and drug targeting. Short papers report seminal results and research approaching conclusion of importance in the field.

The journals’ scope covers all the basic and applied research in drug delivery and targeting at molecular and cellular levels and novel delivery systems. The manuscript submission process is fully electronic to ensure rapid publication of research results. Read now: https://bit.ly/3CSEB62

Aims & Scope – Drug Metabolism Letters

(Continued as Drug Metabolism and Bioanalysis Letters

ISSN (Print): 1872-3128
ISSN (Online): 1874-0758

Latest Issue: Volume 14 , Issue 3 , 2021

Aims & Scope

Drug Metabolism Letters publishes letters, original research papers, mini and full length reviews and guest edited issues in all important aspects of drug delivery, gene delivery, and drug targeting.

The journals’ scope covers all the basic and applied research in drug delivery and targeting at molecular and cellular levels and novel delivery systems. The journal also focuses on all innovative aspects of all pharmaceutical dosage forms and the most advanced research on controlled release, bioavailability and drug absorption, nanomedicines and gene delivery, etc. The manuscript submission process is fully electronic to ensure rapid publication of research results. Read now: https://bit.ly/3cvyCte

Aims & Scope – Infectious Disorders – Drug Targets

(Formerly Current Drug Targets – Infectious Disorders

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Aims & Scope

Infectious Disorders – Drug Targets aims to cover all the latest and outstanding developments in medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews and research articles written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continue to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug design, discovery and development. All aspects related to viral or bacterial diseases including HIV, AIDS and other sexually transmitted diseases (STDs) are also included in the scope of the journal. Read now: https://bit.ly/3cxJNS2

Most Cited Article – Pharmaceutical Lozenges: Recent Trends and Developments with an Update on Research and Patents

Author(s):Mangesh Pradeep KulkarniArun SharmaSagar TanwarParashara Bhattar VandanaSheetu WadhwaGurvinder SinghPardeep Kumar and Rajesh Kumar*

Volume 16, Issue 1, 2022

Published on: 31 January, 2022

Page: [45 – 54]

Pages: 10

DOI: 10.2174/2667387816666211231103759

Abstract

Pharmaceutical oral dosage forms are tremendously preferred by both consumers as well as pharmaceutical manufacturers owing to the plethora of benefits they offer. Lozenges (LZs) are one of the dosage forms that provide a palatable means of drug administration and have great importance with respect to their pharmaceutical applications. LZs offer additional benefits to pediatric and geriatric patients, along with people having problems associated with the gastro-intestinal tract. Dysphagia is a common problem faced by all age groups, which gives rise to the need for LZs. Moreover, the foremost merit presented by the medicated LZs includes its augmented retention time in the oral cavity that results in an enhanced bioavailability for buccal or upper gastro-intestinal disorders. Further, LZs can also be used to bypass the first-pass effect. The present review covers various aspects of LZs such as formulation, manufacturing techniques, evaluation parameters, marketed products, patents, and a compilation of research work that has been done on lozenges as a delivery system. Read more: https://bit.ly/3b9GKPf

The development of new drugs to fight cancer

Ricardo de Souza Pereira

What is it about?

Cancer is a class of diseases with an uncontrolled growth of cells (usually derived from a single cell) beyond the normal limits. The growths often invade adjacent tissues and, sometimes, migrate to other locations of the body (metastasis) via lymph or blood, and promote the growth of new blood vessels from which the cells derive nutrients. Cancerous (malignant) cells can develop from any tissue within the body. These malignant properties of cancers differentiate them from benign tumors, which are self-limited, and do not invade or metastasize [1, 2]. TYPES OF CANCER Cancerous tissues (malignancies) can be divided into those of the blood and blood-forming tissues and cells of the immune system (leukemias and lymphomas) and “solid” tumors, often termed cancer. Cancers can be carcinomas (tumor derived from epithelial tissue) or sarcomas (tumor arising from cells that form muscles and connective tissue) [2]. COSTS OF CANCER The National Institutes of Health in United States estimated overall costs of cancer in 2010 at $263.8 billion: $102.8 billion for direct medical costs (total of all health expenditures); $20.9 billion for indirect morbidity costs (cost of lost productivity due to illness); and $140.1 billion for indirect mortality costs (cost of lost productivity due to premature death) [3, 4]. STATISTICS One in eight deaths worldwide are due to cancer, it is the second and third leading cause of death in economically developed and developing countries, respectively. Cancer affects 1 in 3 of us in our lifetime. It also affects people at all ages with the risk for most types increasing with age. Over 70% of cancers happen to people who are over the age of 60 [5]. Lung cancer, the most common cause of cancer-related death in men and women, is responsible for 1.3 million deaths worldwide annually [1]

Why is it important?

The development of new drugs to fight cancer is essential, as it is a disease with a high rate of mortality and suffering for close relatives of the patient. Read more: https://bit.ly/3OBy2Hk

Most Cited Article – Molecular Docking and Dynamics Simulation of Natural Phenolic Compounds with GSK-3β: A Putative Target to Combat Mortality in Patients with COVID-19

Author(s):Zahra Khamverdi Zeinab Mohamadi and Amir Taherkhani *

Volume 15, Issue 1, 2021

Published on: 15 December, 2021

Page: [16 – 34]Pages: 19

DOI: 10.2174/1872213X14666210916161447

Abstract

Objective: In this study, molecular docking analysis was performed to evaluate the binding affinity of 52 plant-based phenolics with the GSK-3β active sites. Moreover, Molecular Dynamics (MD) simulation was conducted to investigate the stability of interactions between the topranked phenolics and residues within the GSK-3β active sites.

Methods: Molecular docking and MD simulations were performed using AutoDock and Discovery Studio Client software, respectively. Thereafter, pharmacokinetic and toxicological properties of top inhibitors were predicted using bioinformatics web tools. This study aimed to identify the most effective amino acids involved in the inhibition of GSK-3β based on the most stabilizing interactions between the residues and compounds, and also by considering the degree centrality in the ligand- amino acid interaction network for GSK-3β.

Results: It was observed that procyanidin and amentoflavone could bind to the GSK-3β active sites at the picomolar (pM) scale as well as the binding affinity of ΔG binding < -13 kcal/mol, while the inhibition constant for theaflavin 3’-gallate, procyanidin B4, and rutin was calculated at the nanomolar (nM) scale, suggesting that these phenolic compounds can be considered as potential effective GSK-3β inhibitors. Furthermore, Val70, Ala83, Val135, and Tyr134 were found to be the most important amino acids involved in the inhibition of GSK-3β.

Conclusion: The results of the current study may be useful in the prevention of several human disorders, including COVID-19, cancers, Alzheimer’s disease, diabetes mellitus, and cardiovascular diseases. However, wet-lab experiments need to be performed in the future. Read now: https://bit.ly/3RXNW1A

Aims & Scope – Recent Advances in Inflammation & Allergy Drug Discovery

(Recent Patents on Inflammation & Allergy Drug Discovery)

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Volume 15, Issue 2, 2021

Aims & Scope

Recent Advances in Inflammation & Allergy Drug Discovery publishes full-length/mini-reviews, research articles, letters, case reports, perspectives, systematic reviews and thematic issues on inflammation and allergy research, including new strategies of diagnosis, treatment and prevention of allergic and inflammatory diseases. The journal covers all pharmacological aspects of inflammation and allergy, including mediators of inflammation and allergy, as well as cellular processes and molecular mechanisms involved in inflammation, immune dysfunction and allergies in every area of medicine. Articles on important and recent patents in the field are also included in the journal. The journal is essential reading for all researchers involved in inflammation and allergy drug design and discovery. Read now: https://bit.ly/3PHo0oZ

Aims & Scope – Recent Advances on Anti-Infective Drug Discovery

(Formerly Recent Patents on Anti-Infective Drug Discovery

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Volume 16, Issue 3, 2021

Aims & Scope

Recent Advances in Anti-Infective Drug Discovery publishes review and research articles, drug clinical trial studies and guest edited thematic issues on recent patents in the field of anti-infective drug discovery e.g. on novel bioactive compounds, analogs & targets. The journal is essential reading for all researchers involved in anti-infective drug design and discovery. The journal also covers recent research in fast emerging therapeutic areas/targets & therapeutic agents related to anti-infective drug discovery. All aspects related to viral or bacterial diseases including HIV, AIDS and other sexually transmitted diseases (STDs) are also included in the scope of the journal. Read now: https://bit.ly/3ok6Jql

Aims & Scope – Reviews on Recent Clinical Trials

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Volume 17, Issue 4, 2022

Aims & Scope

Reviews on Recent Clinical Trials publishes frontier reviews, original research articles, drug clinical trial studies and guest edited thematic issues on recent clinical trials of major importance. The journal’s aim is to publish the highest quality articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics.

The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials. Read now: https://bit.ly/3NHhehF

Aims & Scope – Recent Patents on Anti-Infective Drug Discovery

Continued as: Recent Advances in Anti-Infective Drug Discovery

ISSN: 2212-4071 (Online)
ISSN: 1574-891X (Print)

Recent Patents on Anti-Infective Drug Discovery publishes review and research articles, drug clinical trial studies and guest edited thematic issues on recent patents in the field of anti-infective drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to anti-infective drug discovery. Read Now: https://bit.ly/39US696

%d bloggers like this: